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ABSTRACT: The tetrazine/trans cyclooctene (TCO) inverse-electron-demand Diels-Alder (IEDDA) reaction is the 
fastest bioorthogonal “click” ligation process reported to date. In this context, TCO reagents have found widespread 
applications, however their availability and structural diversity is still somewhat limited, due to challenges connected 
with their synthesis and structural modification. To address this issue, we developed a novel strategy for the conjugation 
of TCO derivatives to a biomolecule, which allows for the creation of greater structural diversity from a single precursor 
molecule, i.e. trans,trans-1,5-cyclooctadiene [(E,E)-COD] 1, whose preparation requires standard laboratory equipment 
and readily available reagents. This two-step strategy relies on the use of new bifunctional TCO-linkers (5a-11a) for 
IEDDA reactions, which can be synthesized via 1,3-dipolar cycloaddition of (E,E)-COD 1 with different azido-spacers 
(5-11) carrying an electrophilic function (NHS-ester, N-succinimidyl carbonate, p-nitrophenyl-carbonate, maleimide) in 
the -position. Following bioconjugation of these electrophilic linkers to the nucleophilic residue (cysteine or lysine) of a 
protein (step 1), the resulting TCO-decorated constructs can be subjected to a IEDDA reaction with tetrazines 
functionalized with fluorescent or near infrared (NIR) tags (step 2). We successfully used this strategy to label bovine 
serum albumin with the TCO-linker 8a and subsequently reacted it in a cell lysate with the fluorescein-isothiocyanate 
(FITC)-derived tetrazine 12. The same strategy was then used to label the bacterial wall of gram-positive S. aureus 
showing the potential of these linkers for live-cell imaging. Finally, we determined the impact of structural differences of 
the linkers upon the stability of the bioorthogonal constructs. The compounds for stability studies were prepared by 
conjugation of TCO-linkers 6a, 8a and 10a to mAbs, such as Rituximab and Obinutuzumab, and subsequent labelling 
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Reactions that proceed efficiently in biological systems are witnessing widespread applications in the fields of chemistry, 
chemical biology, material sciences and molecular diagnostics, where they enable manipulation of biomolecules, cells 
and particles and their tracking in vitro and in vivo.1 Pioneered by Bertozzi’s Staudinger ligation,2 several bioorthogonal 
reactions were subsequently designed and developed. These reactions include the strain-promoted azide-alkyne 
cycloaddition (SPAAC) and the inverse electron-demand Diels-Alder (IEDDA) reaction.3 In particular, the IEDDA 
reaction between 1,2,4,5-tetrazines and unsaturated compounds, sometimes referred to as Carboni-Lindsey4 reaction, 
has attracted increasing attention in the last decade. In 1990, Sauer described the remarkable kinetics of electron-
deficient tetrazines reacting with different olefins, reporting trans-cyclooctene (TCO) as the most reactive dienophile.5 
In 2008, two groups6,7 almost simultaneously recognised the great potential of the tetrazine/TCO ligation, setting the 
stage for the development of a powerful bioorthogonal reaction.8 Being the fastest click reaction reported to date, this 
process is a powerful tool for studying protein function and dynamics,9,10 through incorporation of TCO reporters via 
chemical,11 genetic12 or enzymatic13 methods. The TCO/tetrazine reaction proved its usefulness also in the 
radiochemistry field,14 where it enabled the generation of modular radioligands in high radiochemical yields and specific 
activity.15–17 In pre-clinical setting, the pre-targeted imaging of living mice18–21 was pioneered by the group of Robillard.22 
Only the IEDDA reaction – among all the bioorthogonal ligations – has so far shown potential for in vivo applications, 
because reactant pairs must display high stability, selectivity and fast reactivity for in vivo applications.18 Several papers 
were published in the last few years describing TCO derivatives with improved reactivity, stability and solubility.23 (E)-
Cyclooct-4-enol is a key TCO derivative which has been conjugated to biomolecules, typically antibodies, via 
functionalization with electrophilic linkers – such as succinimidyl esters and maleimides – reacting with nucleophilic 
lysine or cysteine residues of the biomolecule.22,24,25 Fox and co-workers reported the extremely fast IEDDA kinetics of 
(E)-bicyclo[6.1.0]non-4-ene, due to the 8-membered ring being forced in a half-chair conformation (Fig. 1).26 However, 
enhanced reactivity is often gained at the expense of stability. To overcome this problem, the same research group 
developed another conformationally-strained TCO, the cis-dioxolane-fused trans-cyclooctene (Fig. 1), which displayed 
enhanced stability, while maintaining high reactivity.27 Recently, Lambert et al. reported the smaller and hydrophilic 
trans-5-oxocene,28 following the work of the Kele group, who demonstrated that the lower lipophilicity of a dioxo-TCO 
derivative resulted in improved washout times during imaging experiments.29 Despite these remarkable improvements 
and diverse applications of TCO linkers, their accessibility and commercial availability is still limited,18 which could be 
partly ascribed to the persisting challenges connected with their synthesis and structural modification.30 In this work, we 
aimed to develop a new portfolio of TCO-linkers that could be used for biorthogonal ligations, exploiting the capacity of 
trans,trans-1,5-cyclooctadiene [(E,E)-COD] 1 to undergo a double ‘click’ reaction. Highly strained (E,E)-COD 1 was first 
synthesized in 1958 by Wittig and Polster,31 but it was not until 2011 that the Leeper group studied its unique reactivity, 
elegantly describing the capacity of 1 to undergo two successive click reactions:32 one trans-double bond could be used 
for the conjugation to the target biomolecule, while the other was retained for the subsequent IEDDA bioorthogonal 
reaction with tetrazines. With this concept in mind, we synthesised a set of trans-triazoline-fused trans-cyclooctene 
linkers 5a-11a (Fig. 1) via 1,3-dipolar cycloaddition of (E,E)-COD 1 with different azido-spacers 5-11 carrying an 
electrophilic function. Following bioconjugation of these electrophilic linkers to the nucleophilic residue (cysteine or 
lysine) of a protein (step 1), the resulting TCO-decorated constructs were subjected to IEDDA reaction with tetrazines 
functionalized with a fluorescent dye (step 2). The usefulness of these novel linkers as bioorthogonal reporters was 
demonstrated by the successful labelling of a protein (bovine serum albumin, BSA), bacteria (Staphylococcus aureus) 
and two therapeutic monoclonal antibodies (Rituximab and Obinutuzumab).
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Figure 1. TCO-linkers developed by Fox et al. compared to the novel TCO-linkers 5a-11a in this manuscript.
RESULTS AND DISCUSSION                 
Our novel strategy – based on the use of (E,E)-COD 1 (Scheme 1) as key intermediate – offers innovative possibilities 
of introducing different types of linkers between the biomolecule and the TCO moiety (step 1, Scheme 1) and tuning the 
stability and ligation efficiency of the tagged protein, before performing the IEDDA bioorthogonal ligation (step 2, Scheme 
1). 








































Scheme 1. Schematic representation of the strategy.
Following the experimental procedure reported by Stöckmann et al.,32 (E,E)-COD 1 was synthesized through a 
phosphine-oxide mediated olefin inversion, starting from the cheap starting material (Z,Z)-COD (the original purification 
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steps were modified and optimised, as detailed in the Supporting Information). Diolefin 1 is highly volatile and can be 
stored for months at -20 °C as a solution in hexane or dichloromethane. It can be transferred to other water-immiscible 
organic solvents by exploiting its complexation with Ag(I). Then, by addition of ammonia, 1 can be extracted back into 
the desired organic solvent. The concentration of 1 was accurately measured by 1H NMR using glycine as internal 
standard, allowing careful stoichiometric control in the reaction with the dipolarophile (1.2 equiv).
The high strain energy of (E,E)-COD 1 triggers a first rapid strain-promoted [3+2] cycloaddition with azides, as reported 
by Stöckmann et al.32 Then, the second trans olefinic bond of the resulting 1,2,3-triazoles can be subject to an efficient 
IEDDA reaction with electron-poor tetrazines.32 Although the rate constant for the IEDDA reaction between benzyl azide 
monoadduct of 1 and dipyridyl-tetrazine (k2 = 297±27 M-1s-1 in MeOH)32 is slower than that observed with 
conformationally-strained TCO derivatives (k2 = 22,000±2,000 M-1s-1 in CD3OD for cyclopropane-fused TCO-derivatives, 
see Fig. 1),26,27 it is still in the expected range for this type of reactions.6 Even faster rates can be achieved by performing 
IEDDA reactions in aqueous medium rather than in organic phase, due to the hydrophobic effect.8 Initially, as a proof of 
concept study, we decided to test the reactivity of (E,E)-COD 1 with three model 1,3-dipoles – two azides (2, 3) and a 
nitrone (4) – which afforded, respectively, monoadducts 2a, 3a and diastereomeric mixture 4a/b in excellent yields 
(Scheme 2). Next, the stability of triazoline-fused TCO derivatives 2a and 3a was tested in a protic solvent such as 
CD3OD (70 and 35 mM, respectively) over 2 days at room temperature via NMR. Both compounds were substantially 
stable for several hours, but the formation of by-products became evident after 6 hours (see Fig. S5 and S6, Supporting 





































Scheme 2. Test synthesis of three different bicyclic TCO derivatives.
Next, several electrophilic cross linkers carrying a terminal azide function (5-11) were synthesized and subsequently 
reacted with (E,E)-COD (1) to form trans-1,2,3-triazoline-fused trans-cyclooctene linkers 5a-11a (Scheme 3). The [3+2] 
cycloadditions proceeded in approximatively 2 hours at room temperature and the excess of 1 was simply removed by 
rotary evaporation providing triazolines 5a-11a in nearly quantitative yields. The spacers spanned from a hydrophobic 
and rigid p-methylbenzoate (6a and 7a) to a less hydrophobic acetate (5a) and hydrophilic/flexible short PEG chains 
(8a-11a). Among the PEGylated triazoline-TCO linkers, succinimidyl carbonate derivative 9a was found to be 
exceedingly reactive, releasing N-hydroxysuccinimide even in the presence of traces of moisture present in an organic 
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solvent, such as CD2Cl2. On the other hand, para-nitrophenyl carbonate 10a demonstrated a lower reactivity, in line with 
previous reports.33 Succinimidyl ester 8a represents a compromise in terms of reactivity/stability between the previous 
two. Regarding maleimide-azide cross-linkers 7 and 11, we observed limited stability upon storage even at 4 oC, due to 
the azido group being prone to undergo 1,3-dipolar cycloaddition with the maleimide double bond, forming mixtures of 
the corresponding 1,2,3-triazoles.34,35 Therefore, these linkers had to be freshly synthesized, avoiding their purification 






















































































Scheme 3. General method for the synthesis of triazolines 5a-11a.
With these novel TCO linkers (5a-11a) in hand, we conducted different bioconjugation studies to evaluate their potential 
as bioorthogonal chemical reporters. We selected TCO derivative 8a for testing the coupling with the free lysine residues 
of BSA, because of its favourable overall reactivity/stability properties (see above). TCO-modified BSA was obtained by 
treatment of BSA with 8a and subsequently incubated with different concentrations of fluorescein isothiocyanate (FITC)-
tetrazine 12, which was synthesized by coupling of methyl-tetrazine-amine (13) with commercially available FITC isomer 
I (14) (Scheme 4). The resulting fluorescent product was then assayed by SDS-PAGE and in-gel fluorescent 
measurement, showing that fluorescein labelling of TCO-modified BSA proceeded efficiently in a dose-dependent 
manner with some background labelling of unmodified BSA at higher concentrations of tetrazine 12 (Fig. 2A).
≥95%
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Scheme 4. Synthesis of FITC-tetrazine 12.
To assess if the TCO/tetrazine ligation was specific, just 5% of 8a-modified BSA was added to a cellular lysate and 
incubated with FITC-tetrazine 12, which resulted in a single fluorescent band, corresponding to 70 kDa (BSA), confirming 
the bioorthogonality of the reaction, even in presence of a complex mixture of proteins. This result also confirmed the 
ability of the reaction to occur within minutes at low biomolecule concentrations, which is an important feature for 
bioorthogonal reactions.
Encouraged by these results, the utility of our novel trans-cyclooctene linkers for live-cell imaging was investigated next 
(Fig. 2B,C). As proof of principle in a biological system, the potential of the water-soluble PEG-TCO-linker 8a for labelling 
a bacterial pathogen, S. aureus, via ligation of the free amino groups of peptidoglycan on the bacterial wall was 
assessed. Then, modified and unmodified bacteria, both expressing green fluorescent protein (GFP), were incubated 
with 6-methyl-tetrazine-sulfo-Cy3 (Tz-sulfo-Cy3). Only the peptidoglycan of bacteria treated with 8a showed bright 
fluorescence in the red channel, as a consequence of successful binding to Tz-sulfo-Cy3. This result was confirmed by 
FACS analysis of labelled and unlabelled bacteria (Fig. 2C). Finally, the cytotoxicity of the treatment was examined 
confirming that neither the TCO linker nor the tetrazine treatment affected bacterial growth.
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Figure 2. Bioconjugation of BSA (A) and gram-positive S. aureus bacteria (B and C) using linker 8a. (A) SDS-PAGE analysis of 
unlabelled and 8a-labelled BSA treated with fluorescent tetrazine (Tz) 12 and measurement of specific binding at different probe 
concentrations: BSA was either incubated with 8a (black curve) or not incubated (blue curve) and subsequently treated with FITC-
tetrazine 12. Specific binding (pink curve) was calculated by subtracting the non-specific binding BSA fluorescence from BSA+8a 
fluorescence (i.e. black curve minus the blue curve). (B) Microscopic analysis of S. aureus expressing green fluorescent protein 
(GFP), showing that bacteria modified with compound 8a (lower panel) are selectively labelled by Tz-sulfo-Cy3, whereas those not 
treated with 8a (upper panel) are not labelled. The green channel (GFP, left) shows all the bacteria, the red channel (Cy3, middle) 
shows that only the peptidoglycan of S. aureus previously treated with 8a binds Tz-sulfo-Cy3, as confirmed by merging images from 
GFP and Cy3 channels (right). (C) Flow cytometry analysis of unlabelled (upper panel) and 8a-labelled (lower panel) GFP-expressing 
S. aureus, treated with Tz-sulfo-Cy3: only a minority (1.45%) of non-8a-treated bacteria (upper panel) showed detectable level of 
binding to Tz-sulfo-Cy3, while > 80% of 8a-treated bacteria showed high Cy3 fluorescence (lower panel).
Next, the three different bicyclic TCO derivatives, p-azidomethylbenzoate 6a and short PEG-linkers 8a and 10a, were 
compared for their capacity to successfully modify therapeutic antibodies. These TCO-linkers were chosen to test the 
effect of different spacers (with or without PEG, as in 6a or 8a and 10a respectively) and terminal electrophilic functions 
(NHS or p-nitro phenyl carbonate, as in 6a, 8a or 10a, respectively). As demonstrated in the literature,36–38 the linker is 
a key factor in determining bioorthogonal ligation efficiency with trans-cyclooctene conjugated antibodies. It can affect 
the in vitro/in vivo TCO stability and reactivity,36,37 its accessibility on the antibody surface as well as the aqueous 
solubility38 of the final construct. Rituximab was treated with one of the TCO-linkers and after purification by gel-filtration, 
the number of reactive TCOs per antibody was evaluated by reaction with Tz-sulfo-Cy3 and subsequent absorbance 
measurements at 280 and 553 nm. Linker 6a failed to provide any construct carrying reactive TCO handles, causing 
instead antibody precipitation, as a likely result of aggregation. Presumably, the p-azidomethylbenzoate linker increases 
the protein surface hydrophobicity, thus reducing the construct stability in aqueous solution. We next explored whether 
the introduction of a short PEG spacer could afford a stable construct with a reproducible TCO/mAb ratio (TAR). We 
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firstly tested succinimidyl linker-TCO 8a. Although it enabled successful labelling of BSA and S. aureus at neutral pH 
(7.4), it proved to be fast hydrolysing at basic pH (> 8), leading to quite variable TCO/mAb ratios (TAR ranged from 0.1 
to 0.6). For this reason, we switched to the p-nitro phenyl carbonate activated linker (10a), which is less susceptible to 
hydrolysis. This allowed us to conduct the conjugation at pH 9.5, to promote the reaction between the nucleophilic amine 
and the aromatic carbonate group. Linker 10a provided a reproducible TAR of 0.9 ± 0.0 (n=4) for Rituximab conjugation 
(Fig. 3), with more than 94% of mAb recovered after click reaction. Similar TARs were measured for Obinutuzumab 
conjugation and size-exclusion chromatograms at 280 and 553 nm showed clean final constructs, with no significant 
aggregates or fragments (Fig. 4, S3). Cy3-linked TCO-Rituximab remained intact for at least seven days in PBS at 24°C. 
Although some antibody degradation was visible at 280 nm, we observed very little dye release, thus indicating the 

















Figure 3. Structure of Tz-sulfo-Cy3-labelled 10a-Rituximab.
7.6
6.7










Figure 4. Size-exclusion chromatograms at 280 and 553 nm of Tz-sulfo-Cy3-labelled 10a-Rituximab (Rt 7.6). The conjugation of Tz-
sulfo-Cy3 to 10a-Rituximab, which absorbs at 280 nm, can be observed by the presence of the peak at 553 nm [maximum absorption 
of Cy3]. The peak at 553 nm, which originates exclusively from the fluorophore sulfo-Cy3, indicates that 10a-Rituximab was efficiently 
conjugated to the fluorescent tag, as a consequence of successful IEDDA reaction between the tetrazine dye and the TCO handle 
on the antibody.
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CONCLUSION               
In summary, we synthesized and used novel TCO-linkers 5a-11a derived from trans,trans-1,5-cyclooctadiene 1 for the 
conjugation to different types of biomolecules, which were subsequently subjected to bioorthogonal ligation with 
tetrazine tags. This strategy offers flexibility in the choice of the linker, which plays an important role on the stability and 
ligation efficiency of the tagged biomolecule, such as BSA. The novel TCO-linkers proved their usefulness as 
bioorthogonal ligation reporters. Linker 8a reacted bioorthogonally in a cellular lysate and enabled the labelling of 
bacteria, such as S. aureus, showing its potential for live-cell imaging. Furthermore, the short PEG linker 10a could be 
used for decorating the surface of monoclonal antibodies, such as Rituximab and Obinutuzumab, with functional handles 
without producing any detectable mAb aggregation or precipitation. In conclusion, these novel linkers represent a 
versatile and valuable addition to the bioorthogonal ligation toolkit. The use of [(E,E)-COD] 1 as a precursor significantly 
expands the structural diversity that can be installed on TCO scaffolds, by taking advantage of the first ‘click reaction’ 
leading to TCO-linkers 5-11a. Furthermore, using inexpensive and readily available [(Z,Z)-COD] as starting material for 
preparing 1 offers an economic and laboratory-based alternative to purchasing commercial TCO derivatives, without 
the need of using specialized equipment, such as UV reactor, pumps and Ag+-loaded columns.30 Currently, the only 
shortcoming of this method is the relatively limited efficiency of the three-step conversion of [(Z,Z)-COD] into 1,32 which 
could be addressed by developing a more direct and scalable procedure for performing this transformation.
EXPERIMENTAL PROCEDURES                 
General information. Chemicals were purchased from Sigma-Aldrich unless otherwise specified. 6-methyl-tetrazine 
sulfo-Cy3 was purchased from Jena Bioscience Ltd. Reactions were monitored by thin-layer chromatography (TLC) on 
Merck silica gel glass plates (60 F254). Visualisation was accomplished by UV light (254 nm) and/or staining with ceric 
ammonium molybdate or KMnO4. Flash chromatography was performed using silica gel (60 Å, particle size 40–63 μm) 
purchased from Merck. 1H NMR and 13C NMR spectra were recorded on a Bruker AVANCE III 400 NMR spectrometer 
and calibrated using residual non-deuterated solvent as internal reference. Chemical shifts (δ) are reported in parts per 
million (ppm) and coupling constants (J) are given in Hertz (Hz). When necessary, resonances were assigned using 
two-dimensional experiments (COSY and HSQC). Specific signals of minor diastereomers in diastereomeric mixtures 
are indicated by an asterisk. Mass Analyses (MS) were performed using an Agilent 1200 HPLC system coupled to an 
Agilent G6120 single quadrupole detector equipped with an electrospray ionisation (ESI) source in direct infusion 
modality. ESI-MS spectra were recorded in positive mode. The tagged antibody was analysed by size-exclusion 
chromatography using a Jasco HPLC system equipped with a Sepax Zenix-C SEC-300 column (300 Å, 7.8 × 300 mm) 
and Sepax Zenix-C SEC-300 guard column (Sepax Technologies Inc., Newark, DE, USA) using a mixture of 0.05 mol/L 
sodium phosphate, 0.15 mol/L sodium chloride (pH 6.8), and 0.01 mol/L NaN3, as the eluent at a flow rate of 1 
mL/minute.
General procedure for the synthesis of triazoline monoadducts (2a-3a, 5a-11a). To (E,E)-COD (1, 1.2 eq., 36 mM 
in DCM), the appropriate azide (0.05-0.1 mmol, 1.0 eq.) dissolved in DCM (linker 2-10, 28 mM) or EtOAc (linker 11) was 
added while stirring at room temperature. When the reaction had finished (typically 2 h, TLC), the solvent and excess 
of (E,E)-COD were removed under reduced pressure. See the separate compounds for follow-up purification strategy.
Methyl-4-(((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)methyl)benzoate (2a). Flash 
chromatography (n-Hex/EtOAc 8.5:1.5). Crystalline solid (90% yield). Rf = 0.3 (n-Hex/EtOAc 7:3). 1H NMR (400 MHz, 
CDCl3) δ: 8.01 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 5.46 (ddd, J = 15.8, 10.8, 3.4 Hz, 1H), 5.30 (ddd, J = 15.8, 
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10.8, 3.4 Hz, 1H), 4.91 (d, J = 15.6 Hz, 1H), 4.52 (d, J = 15.6 Hz, 1H), 3.92 (m, 3H), 3.91 (td, J = 11.2, 1,6 Hz, 1H), 2.71 
– 2.66 (m, 1H), 2.60 (td, J = 11.2, 1,6 Hz, 1H), 2.42 – 2.26 (m, 3H), 2.18 – 1.98 (m, 2H), 1.67 – 1.52 (m, 1H), 1.51 – 
1.34 (m, 1H). 13C NMR (101 MHz, CDCl3) δ: 166.8, 141.6, 135.7, 134.0, 129.9 (2C), 129.7, 128.3 (2C), 87.2, 65.8, 52.4, 
52.2, 37.7, 35.6, 33.3, 32.4. MS (ESI): m/z calcd C17H21N3O2: 300.2 [M+H]+; found: 272.1 [M-N2+H]+, 290.1 [M-
N2+H2O+H]+.
2-(2-(2-(2-((3aSR,9aSR,E)-3a,4,5,8,9,9a-Hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)ethoxy)ethoxy)ethoxy)ethan-1-
ol (3a). Filtration through a pad of silica gel (n-Hex/Ac2O 1:1). Clear oil (97% yield). Rf = 0.24 (n-Hex/Ac2O 1:1). 1H NMR 
(400 MHz, D2O) δ: 5.75 – 5.51 (m, 2H), 4.01 (t, J = 11.2 Hz, 1H), 3.91 – 3.55 (m, 16H), 3.23 (t, J = 11.2 Hz, 1H), 2.65 – 
2.13 (m, 6H), 1.72 (m, 2H). 13C NMR (101 MHz, CD3OD) δ: 135.1, 134.3, 85.1, 72.3, 70.3, 70.26, 70.2, 70.0, 69.9, 68.7, 
66.9, 60.8, 37.3, 35.2, 32.8, 32.0. MS (ESI): m/z calcd C16H29N3O4: 328.2 [M+H]+; found: 300.1 [M-N2+H]+, 318.1 [M-
N2+H2O+H]+.
(3RS,3aRS,9aSR,E)-2-Methyl-3-phenyl-2,3,3a,4,5,8,9,9a-octahydrocycloocta[d]isoxazole (4a/b). α-Phenyl-N-
methylnitrone was synthesized as reported by Bigdeli et al.39 in 50% yield. In short: nitrone (10 mg, 0.074 mmol, 1.0 
eq.) was dissolved in DCM and added to (E,E)-COD (1, 4.8 mL, 20 mM, 1.3 eq.). After 4 h, some nitrone was still present 
(TLC, DCM/MeOH 9.5:0.5), therefore the reaction was left stirring overnight. The completion of reaction was checked 
by TLC. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography 
(100% DCM) to afford 16 mg of diastereomeric mixture (60:40 ratio) of monoadducts (88%). 1H NMR (400 MHz, CDCl3) 
δ: 7.27 – 7.1 (m, 5H), 5.5 – 5.3 (m, 2H), 3.68 (ddd, J = 10.8, 5.2, 1.6 Hz, 1H), 3.45 (d, J = 8.8 Hz, 0.6H, H-3), 2.89 (d, J 
= 9.6 Hz, 0.4H, H-3*), 2.44 (s, 1.8H, CH3), 2.36 (s, 1.2H, CH3*), 2.34 – 2.06 (m, 5H), 1.83 – 1.72 (m, 2H), 1.41 (m, 1H), 
1.15 – 1.10 (m, 1H). 13C NMR (101 MHz, CDCl3) δ: 138.3*, 137.7, 135.5*, 134.3, 133.5, 132.8*, 128.6 (2C), 128.5* (2C), 
128.4 (2C), 128.3* (2C), 127.9*, 127.4, 87.9, 86.2*, 80.9*, 77.9, 62.4*, 55.2, 43.4, 43.2*, 40.9*, 37.3, 34.6, 34.1, 34.07*, 
33.4*, 32.6*, 31.9. MS (ESI): m/z calcd C16H21NO: 244.2 [M+H]+; found: 244.1 [M+H]+.
2,5-Dioxopyrrolidin-1-yl-2-((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)acetate (5a). 
Crystalline solid (quantitative yield). Rf = 0.2 (n-Hex/EtOAc 1:1). 1H NMR (400 MHz, CD2Cl2) δ: 5.59 – 5.46 (m, 2H), 
4.90 (d, J = 17.2 Hz, 1H), 4.36 (d, J = 17.2 Hz, 1H), 4.01 (td, J = 11.2, 1.6 Hz, 1H), 3.01 (td, J = 11.2, 1.6 Hz, 1H), 2.83 
(s, 4H), 2.7 – 2.65 (m, 1H), 2.49 – 2.14 (m, 4H), 2.17 – 2.09 (m, 1H), 1.76 – 1.60 (m, 2H). 13C NMR (101 MHz, CD2Cl2) 
δ: 168.8 (2C), 165.1, 135.7, 134.0, 88.9, 65.6, 47.3, 36.9, 35.7, 33.2, 32.2, 25.6 (2C). MS (ESI): m/z calcd C14H18N4O4: 
307.1 [M+H]+; found: 297.1 [M-N2+H2O+H]+.
2,5-Dioxopyrrolidin-1-yl-4-(((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-
yl)methyl)benzoate (6a). Crystalline solid (quantitative yield). Rf = 0.27 (n-Hex/EtOAc 1:1). 1H NMR (400 MHz, CD3Cl) 
δ: 8.16 – 8.05 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 5.47 (ddd, J = 16.1, 10.8, 3.5 Hz, 1H), 5.36 (ddd, J = 16.1, 
10.8, 3.5 Hz, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.57 (d, J = 15.7 Hz, 1H), 3.92 (td, J = 11.2, 1.6 Hz, 1H), 2.91 (s, 4H), 2.72 
– 2.68 (m, 1H), 2.59 (td, J = 11.2, 1.6 Hz, 1H), 2.45 – 2.27 (m, 3H), 2.13 – 2.03 (m, 2H), 1.66 – 1.41 (m, 2H). 13C NMR 
(101 MHz, CD3Cl) δ: 169.3 (2C), 161.5, 144.1, 135.8, 133.9, 131.0 (2C), 128.7 (2C), 124.6, 87.4, 65.9, 52.3, 37.6, 35.6, 
33.3, 32.3, 25.7 (2C). MS (ESI): m/z calcd C20H22N4O4: 383.2 [M+H]+; found: 373.1 [M-N2+H2O+H]+. 
N-(2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-4-(((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]
triazol-1-yl)methyl)benzamide (7a). Crystalline solid (quantitative yield). Rf = 0.18 (n-Hex/EtOAc 3:7). 1H NMR (400 
MHz, CD3Cl) δ: 7.73 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 8.4, 2H), 6.77 (br, 1H, N-H), 6.73 (s, 2H), 5.46 (ddd, J = 15.9, 10.8, 
3.4 Hz, 1H), 5.31 (ddd, J = 15.9, 10.8, 3.4 Hz, 1H), 4.90 (d, J = 15.6 Hz, 1H), 4.48 (d, J = 15.6 Hz, 1H), 3.90 (td, J = 
11.2, 1.6 Hz, 1H), 3.84 – 3.81 (m, 2H), 3.67 – 3.63 (m, 2H), 2.69 – 2.65 (m, 1H), 2.61 (td, J = 11.2, 1.6 Hz, 1H), 2.43 – 
2.26 (m, 3H), 2.12 – 2.02 (m, 2H), 1.66 – 1.54 (m, 1H), 1.48 – 1.38 (m, 1H). 13C NMR (101 MHz, CDCl3) δ: 171.1 (2C), 
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167.4, 140.1, 135.7, 134.3 (2C), 134.0, 133.6, 128.5 (2C), 127.4 (2C), 87.2, 65.7, 52.2, 39.9, 37.6, 37.5, 35.6, 33.3, 
32.4. MS (ESI): m/z calcd C22H25N5O3: 408.2 [M+H]+; found: 380.1 [M-N2+H]+, 398.1 [M-N2+H2O+H]+. 
2,5-Dioxopyrrolidin-1-yl-14-((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)-3,6,9,12-
tetraoxatetradecanoate (8a). Clear oil (quantitative yield). Rf = 0.3 (DCM/MeOH 9:1). 1H NMR (400 MHz, CDCl3) δ: 5.59 
– 5.36 (m, 2H), 4.50 (s, 2H), 3.84 (td, J = 11.2, 1.6 Hz, 1H), 3.78 – 3.76 (m, 2H), 3.72 – 3.46 (m, 14H), 2.98 (td, J = 11.2, 
1.6 Hz, 1H), 2.83 (s, 4H), 2.71 – 2.66 (m, 1H), 2.48 – 2.29 (m, 3H), 2.24 – 2.14 (m, 2H), 1.71 – 1.52 (m, 2H). 13C NMR 
(101 MHz, CD3Cl) δ: 168.8 (2C), 165.9, 135.6, 134.4, 86.6, 71.3, 70.7 (2C), 70.6 (2C), 70.4, 69.5, 67.3, 66.5, 48.0, 37.7, 
35.9, 33.4, 32.6, 25.6 (2C). MS (ESI): m/z calcd C22H34N4O8: 483.2 [M+H]+; found: 455.1 [M-N2+H]+.
2,5-Dioxopyrrolidin-1-yl (2-(2-(2-(2-((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl) carbonate (9a). Clear oil (quantitative yield). Rf = 0.18 (EtOAc/n-Hex 8:2). 1H NMR (400 
MHz, CD2Cl2) δ: 5.54 – 5.41 (m, 2H), 4.44 – 4.41 (m, 2H), 3.81 (td, J = 11.2, 1.6 Hz, 1H), 3.75 – 3.72 (m, 2H), 3.7 – 
3.45 (m, 12H), 2.93 (td, J = 11.2, 1.6 Hz, 1H), 2.79 (s, 4H), 2.66 – 2.61 (m, 1H), 2.45 – 2.28 (m, 3H), 2.24 – 2.14 (m, 
2H), 1.66 – 1.51 (m, 2H). 13C NMR (101 MHz, CD2Cl2) δ: 168.7 (2C), 151.6, 135.5, 134.4, 86.8, 70.8, 70.6, 70.5, 70.4, 
70.37, 69.2, 68.3, 67.2, 48.2, 37.7, 36.0, 33.3, 32.5, 25.5 (2C). MS (ESI): m/z calcd C21H32N4O8: 469.2 [M+H]+; found: 
441.2 [M-N2+H]+, 459.2 [M-N2+H2O+H]+.
2-(2-(2-(2-((3aSR,9aSR,E)-3a,4,5,8,9,9a-Hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl (4-
nitrophenyl) carbonate (10a). Flash chromatography (n-Hex/Ac2O 7:3). Clear oil (95% yield). Rf = 0.23 (n-Hex/Ac2O 
7:3). 1H NMR (400 MHz, CDCl3) δ 8.30 – 8.25 (d, J = 9.2 Hz, 2H), 7.40 – 7.36 (d, J = 9.2 Hz, 2H), 5.55 – 5.42 (m, 2H), 
4.44 – 4.42 (m, 2H), 3.86 (td, J = 11.2, 1.6 Hz, 1H), 3.81 – 3.79 (m, 2H), 3.71 – 3.49 (m, 12H), 2.98 (td, J = 11.2, 1.6 
Hz, 1H), 2.74 – 2.70 (m, 1H), 2.50 – 2.30 (m, 3H), 2.25 – 2.15 (m, 2H), 1.70 – 1.55 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ: 155.5, 152.5, 145.4, 135.6, 134.4, 125.3 (2C), 121.8 (2C), 86.7, 70.74, 70.73, 70.7, 70.4, 69.5, 68.7, 68.3, 67.3, 48.0, 
37.8, 35.9, 33.4, 32.6. MS (ESI): m/z calcd C23H32N4O8: 493.2 [M+H]+; found: 465.2 [M-N2+H]+, 483.2 [M-N2+H2O+H]+.
1-(2-(2-(2-(2-((3aSR,9aSR,E)-3a,4,5,8,9,9a-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-
1H-pyrrole-2,5-dione (11a). Filtration through a pad of silica gel (n-Hex/EtOAc 2:8). Clear oil (85% yield over two steps). 
Rf = 0.2 (EtOAc/n-Hex 8:2). 1H NMR (400 MHz, CD3Cl) δ: 6.69 (s, 2H), 5.55 – 5.42 (m, 2H), 3.86 (td, J = 11.2, 1.6 Hz, 
1H), 3.74 – 3.48 (m, 16H), 2.99 (td, J = 11.2, 1.6 Hz, 1H), 2.74 – 2.69 (m, 1H), 2.51 – 2.31 (m, 3H), 2.26 – 2.16 (m, 2H), 
1.70 – 1.54 (m, 2H). 13C NMR (101 MHz, CDCl3) δ: 170.6 (2C), 135.6, 134.4, 134.2 (2C), 86.7, 70.7, 70.6, 70.4, 70.1, 
69.5, 67.8, 67.3, 48.0, 37.8, 37.1, 35.9, 33.4, 32.6. MS (ESI): m/z calcd C20H30N4O5: 407.2 [M+H]+; found: 379.2 [M-
N2+H]+, 497.2 [M-N2+H2O+H]+.
2-(6-Hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)thioureido)benzoic acid (FITC-
tetrazine 12). (4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenyl)methanamine (TFA salt) (73 mg, 0.23 mmol, 1.0 eq.) was 
dissolved in dry DMF (3 mL) under nitrogen atmosphere. Fluorescein-5-isothiocyanate (≥ 90% purity, 105 mg, 0.26 
mmol, 1.2 eq.) was added in dry DMF (3 mL), followed by DIPA (65 µL, 0.46 mmol, 2.0 eq.). The reaction was stirred 
overnight at room temperature (rt). After addition of NH4Cl (10 mL, sat.aq.), the crude product was extracted in EtOAc 
(3 x 10 mL). The organic phase was washed with brine (10 mL). The desired product was purified by flash 
chromatography (gradient from 5% to 15% MeOH in DCM) to yield 112 mg of FITC-tetrazine 12 (yield 85%) as a red 
solid. Rf = 0.3 (DCM/MeOH 95/05). 1H NMR (400 MHz, CD3OD) δ: 8.43 (d, J = 8.4 Hz, 2H), 8.13 (m, 1H), 7.74 (dd, J = 
8.0, 2.0 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 8.4 Hz, 1H), 6.63 – 6.59 (m, 4H), 6.47 (dd, J = 8.8, 2.4 Hz, 2H), 
4.93 (s, 2H), 2.96 (s, 3H). 13C NMR (101 MHz, CD3OD) δ: 181.9, 169.8, 167.2 (2C), 163.6 (2C), 160.1, 152.8 (2C), 
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148.1, 143.3, 140.9, 130.7 (2C), 129.0 (2C), 128.9, 128.0 (2C), 127.6 (2C), 124.5, 118.9, 112.4 (2C), 110.1 (2C), 102.2 
(2C), 47.5, 19.8. MS (ESI): m/z calcd C32H24N6O4S: 591,1 [M+H]+; found: 591,1 [M+H] +.
BSA labelling. Bovine serum albumin (BSA) conjugate were prepared by the treatment of BSA (5 mg/mL) with 
compound 8a (190 µL of 4 mM, 10 eq.) in PBS (pH 7.4) for 2 hours and subsequent purification by spin-filter (Vivaspin 
6, 50 kDa) using PBS (pH 7.4) as buffer.
In-gel fluorescence analysis of BSA conjugates. TCO-modified BSA (1.8 mg/mL) and unmodified BSA (1.8 mg/mL) 
were diluted (1:2) in PBS (pH 7.4) and treated with FITC-tetrazine 12 (1-100 μM) for 30 minutes at room temperature. 
Alternatively, 5% of TCO-modified BSA (1.8 mg/mL) was added to total cell lysed from Hela cells (1 mg/mL) and 
incubated with 15 µL FITC-tetrazine 12 (60 µM) for 5 or 30 minutes. 10 μL of sample buffer 2X (4% SDS, 20% glycerol, 
125 mM Tris pH 6.8, 10% -mercapto-ethanol, 0.001% Bromophenol blue) were added to 10 μL of each BSA sample. 
The samples were heated for 5 minutes at 99˚C and analysed by gel electrophoresis using 10% polyacrylamide gels 
and running buffer 10X (25 mM Tris base, 192 mM glycine, 3.5 mM SDS, 1 L MilliQ water) diluted (1:10) in MilliQ water. 
Gel pictures were taken with a UV transilluminator camera and quantified with ImageJ software. Total protein loading 
was confirmed by subsequent staining with Coomassie Brilliant Blue. Specific binding at each probe concentrations was 
calculated by subtracting the non-specific binding BSA fluorescence from BSA+8a fluorescence.
Bacterial cell culture and labelling experiments. Bacterial cells (Staphylococcus aureus SH1000-GFP) from a single 
colony were grown overnight in LB broth at 37 °C with agitation. An aliquot was taken and diluted (1:100) in fresh broth 
and cultured for another ~ 2 hours to ensure the bacteria were in the logarithmic phase. Then, 2 aliquots of 1 mL (at a 
bacterial concentration of a million microliter) were spun down at 3000 g and suspended in 0.5 mL PBS (pH 7.4) or 0.5 
mL of compound 8a in PBS (1 mg/mL, pH 7.4) for 1 h 30 min. The aliquots were spun down at 3000 g, washed twice 
with 0.5 mL PBS (pH 7.4), spun down again and the bacterial pellet was suspended in 0.5 mL PBS (pH 7.4), followed 
by incubation with 2 μL of 6-methyl-tetrazine-sulfo-Cy3 (5.5 mM stock solution) at room temperature for 10 min. The 
bacteria were then sp down and washed twice with 0.5 mL PBS (pH 7.4) before the final dilution of the bacteria in PBS 
(pH 7.4) for microscopic analysis. 
Microscopic analysis of stained cells. For epi-fluorescence microscopy, 10 μL of the bacterial cell suspension was 
placed on a glass slide. A coverslip was pressed down on the cell droplet to give a single layer of cells on the glass 
slides. White light and fluorescence images were taken on a microscope (Zeiss Imager M2) equipped with a filter cube 
suitable for detection of GFP and Cy3 fluorescence. A Plan-NeoFluar × 100 oil lenses from Zeiss was used to visualise 
the bacterial cells. All images were captured with the exposure time of 150 ms (green fluorescence) or 1600 ms (red 
fluorescence).
Flow cytometry analysis of stained cells. The samples were prepared and labelled following the same protocol 
described for microscopy. In addition, cells were resuspended in 4% PFA incubated for 15 minutes at room temperature, 
then pelleted again, washed once in PBS and then resuspended in PBS (pH 7.4). 300 μL aliquots were filtered through 
a 35 μm filter (Nalgene) before analysis. The samples were analysed on a BD Fortessa analyser (BD Biosciences). 
Data analysis was performed with FlowJo.
Antibody modification. 3.0 mg of Rituximab (MabThera/Rituxan Roche, 10 mg/mL in solution for injection) was 
modified with 55 molar equivalents of compound 10a, added in 3 aliquots after homogeneous mixing (565 μg in 56.5 μL 
DMSO). The pH was adjusted to 9.5 with 0.1 M sodium carbonate. The reaction was carried out under agitation for 2 h 
at 24 °C in the dark. Subsequently, the TCO-modified mAb was purified by PD10 (GE Healthcare Life Sciences, NJ, 
USA), using PBS (pH 7.4) as eluent. The protein concentration was determined by absorbance measurements at 280 
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nm (NanoDrop®) using a calibration curve of Rituximab. The final concentration of TCO-modified mAb was 1.5 mg/mL 
in PBS (pH 7.4). 
3.0 mg of Obinutuzumab (Gazyva/Gazyvaro Roche 25 mg/mL in solution for injection) was buffer exchanged to 0.9% 
NaCl by PD10 and modified as described above. The final concentration of TCO-modified mAB was 1.3 mg/mL in PBS 
(pH 7.4).
TAR measurement: An aliquot of TCO-modified mAb (250 μL) was treated with 10 eq. of 6-methyl-tetrazine-sulfo-Cy3 
for 1 h at 24 °C. Subsequently, the labelled mAb was purified by PD10, using PBS (pH 7.4) as eluent. The solution was 
concentrated to 250 µL using an Amicon Ultra-4 (cut-off 10 kDa) centrifugal device. Protein and fluorophore (sulfo-Cy3) 




Experimental procedures for the synthesis of heterobifunctional TCO-linkers 5-11, SDS-page analyses, stability studies, 
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